Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Mar 18, 2021

SEC Form 4
FORM 4			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940													OMB Number: 3235-0287 Estimated average burden hours per response:
1. Name and Address of Reporting Person* Leavitt Chase C.			2. Issuer Name and Ticker or Trading Symbol Lineage Cell Therapeutics, Inc. [ LCTX ]									(Check all applicable) Director	Officer (give title	5. Relationship of Reporting Person(s) to Issuer		10% Owner Other (specify
(Last) (First) (Middle) C/O LINEAGE CELL THERAPEUTICS, INC. 2173 SALK AVENUE, SUITE 200					3. Date of Earliest Transaction (Month/Day/Year) 03/15/2021									X below) below) General Counsel/Secretary
(Street) CARLSBAD CA			92008	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting
(City) (State)			(Zip)											Person
			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date				(Month/Day/Year)	if any	2A. Deemed Execution Date, (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following		(I) (Instr. 4)	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership
									Code V	Amount		(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
			Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned			(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Conversion Date or Exercise (Month/Day/Year) Price of Derivative Security		3A. Deemed 4. Execution Date, if any (Month/Day/Year) 8)		Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
													Amount or		(Instr. 4)

Date Exercisable Expiration Date Title

Explanation of Responses:

Employee Stock Option (Right to Buy)

1. One quarter of the options shall vest on March 15, 2022 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.

Code V (A) (D)

\$2.43 03/15/2021 ^A 699,100 (1) 03/15/2031 Common

/s/ Chase C. Leavitt 03/17/2021

Number of Shares

Shares 699,100 \$0.00 699,100 ^D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.